NEW YORK (GenomeWeb News) – CombiMatrix will net an additional $1.2 million in funding after its stockholders approved the sale of the company's Series C Preferred Stock, the company said today.

CombiMatrix raised $1.2 million in a first tranche of equity financing in May. The second tranche of that financing was subject to stockholder approval, which was granted at the firm's annual meeting, held on June 27.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.